ARGX Stock Sinks as Argenx Scraps Late-Stage Trial
Argenx (ARGX) discontinued a Phase 3 trial for Vyvgart in Sjögren's disease after it was unlikely to meet its primary endpoint. The decision caused a 24% drop in shares from their year-to-date high. Despite this, ARGX reported strong Q2 sales of $1.5 billion and positive Phase 2 results for FB102 in celiac disease. Analysts maintain a 'Strong Buy' rating with a mean price target of $1,188.
How this was made
The 30-second read
Why it matters
The announcement caused a sharp sell‑off, reflecting the loss of a major revenue opportunity and raising concerns about the company's pipeline execution.
Market read
The trial discontinuation is a primary catalyst for a significant price decline, making the news highly relevant for traders with exposure to ARGX or the broader biotech sector.
What to watch
Positive Phase 2 data for FB102 in celiac disease may provide a new growth avenue.
Background
Argenx (NASDAQ:ARGX) announced the termination of its Phase 3 UNITY study for Vyvgart in Sjögren's disease after a data‑monitoring committee deemed success unlikely.
Ticker impact
Argenx discontinued its Phase 3 UNITY trial for Vyvgart in Sjögren's disease, triggering a ~24% stock drop.
likely pressure as the market prices in the lost growth opportunity
Discontinuation of a late‑stage trial is a material negative event for a biotech; the stock already fell 24% and no offsetting news outweighs the loss.
Market effects
Biotech sector may see heightened scrutiny of late‑stage trial pipelines.
US biotech investors could reassess risk exposure.
Limited to biotech and pharma investors worldwide.
Counterpoint
The company retains a strong cash position and a growing Vyvgart franchise, which could support a rebound if other pipeline assets succeed.
Key entities
- companyArgenx
Biopharmaceutical company developing Vyvgart and other antibody therapies.
- productVyvgart
Argenx's blockbuster drug targeting autoimmune diseases.
